DLA PIPER LLP (US)

Lobbying for AVALYN PHARMA INC. · Biopharmaceutical company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $40,000.00 income · posted Jan 16, 2026

Lobbying activity 2

Medical/Disease Research/Clinical Labs

Issues related to lung disease and rare disease.

Health Issues

Issues related to lung disease and rare disease.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.